share_log

In8bio | 10-Q: Q2 2024 Earnings Report

In8bio | 10-Q: Q2 2024 Earnings Report

In8bio | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/09 04:16

Moomoo AI 已提取核心訊息

IN8bio reported a net loss of $8.6 million for Q2 2024, compared to $7.7 million in Q2 2023. Research and development expenses increased to $5.2 million from $4.1 million, primarily due to higher personnel costs and clinical trial expenses. General and administrative expenses remained relatively flat at $3.5 million.The company ended the quarter with $10.2 million in cash, which is expected to fund operations only into January 2025, raising substantial doubt about its ability to continue as a going concern. During Q2, IN8bio raised $3.5 million through its ATM program. The company is exploring additional financing options including equity/debt offerings and strategic partnerships to extend its runway.IN8bio continues to advance its clinical programs, including the Phase 2 trial of INB-400 for glioblastoma and Phase 1 trials of INB-200 and INB-100. Recent data presented at medical conferences showed promising results, with 92% of evaluable GBM patients exceeding median progression-free survival with INB-200/400 and 100% of leukemia patients achieving durable complete remission with INB-100 through one year.
IN8bio reported a net loss of $8.6 million for Q2 2024, compared to $7.7 million in Q2 2023. Research and development expenses increased to $5.2 million from $4.1 million, primarily due to higher personnel costs and clinical trial expenses. General and administrative expenses remained relatively flat at $3.5 million.The company ended the quarter with $10.2 million in cash, which is expected to fund operations only into January 2025, raising substantial doubt about its ability to continue as a going concern. During Q2, IN8bio raised $3.5 million through its ATM program. The company is exploring additional financing options including equity/debt offerings and strategic partnerships to extend its runway.IN8bio continues to advance its clinical programs, including the Phase 2 trial of INB-400 for glioblastoma and Phase 1 trials of INB-200 and INB-100. Recent data presented at medical conferences showed promising results, with 92% of evaluable GBM patients exceeding median progression-free survival with INB-200/400 and 100% of leukemia patients achieving durable complete remission with INB-100 through one year.
In8bio報告2024年第二季度淨虧損860萬美元，較2023年第二季度的770萬美元有所增加。研發費用從410萬美元增加至520萬美元，主要由於人力成本和臨牀試驗費用上升。一般和行政費用保持相對平穩，爲350萬美元。公司在季度末的現金餘額爲1020萬美元，預計只能支持運營到2025年1月，這引發了對其持續經營能力的重大懷疑。在第二季度，In8bio通過其ATm計劃募集了350萬美元。公司正在探索包括股權/債務發行和戰略合作伙伴關係在內的額外融資選項，以延長其資金鍊。In8bio繼續推進其臨牀項目，包括針對膠質母細胞瘤的INb-400二期試驗和INb-200及INb-100的一期試驗。在最近的醫學會議上，展示的數據顯現出令人鼓舞的結果，92%的可評估膠質母細胞瘤患者在使用INb-200/400時超越了中位無進展生存期，100%的白血病患者在使用INb-100後獲得了持續的完全緩解，持續時間超過一年。
In8bio報告2024年第二季度淨虧損860萬美元，較2023年第二季度的770萬美元有所增加。研發費用從410萬美元增加至520萬美元，主要由於人力成本和臨牀試驗費用上升。一般和行政費用保持相對平穩，爲350萬美元。公司在季度末的現金餘額爲1020萬美元，預計只能支持運營到2025年1月，這引發了對其持續經營能力的重大懷疑。在第二季度，In8bio通過其ATm計劃募集了350萬美元。公司正在探索包括股權/債務發行和戰略合作伙伴關係在內的額外融資選項，以延長其資金鍊。In8bio繼續推進其臨牀項目，包括針對膠質母細胞瘤的INb-400二期試驗和INb-200及INb-100的一期試驗。在最近的醫學會議上，展示的數據顯現出令人鼓舞的結果，92%的可評估膠質母細胞瘤患者在使用INb-200/400時超越了中位無進展生存期，100%的白血病患者在使用INb-100後獲得了持續的完全緩解，持續時間超過一年。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點